Pelabresib + Ruxolitinib + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Myelofibrosis (PMF)
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Trial Timeline
Apr 15, 2026 → Dec 27, 2030
NCT ID
NCT07357727About Pelabresib + Ruxolitinib + Placebo
Pelabresib + Ruxolitinib + Placebo is a phase 3 stage product being developed by Novartis for Primary Myelofibrosis (PMF). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07357727. Target conditions include Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF).
What happened to similar drugs?
20 of 20 similar drugs in Primary Myelofibrosis (PMF) were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07357727 | Phase 3 | Recruiting |
| NCT04603495 | Phase 3 | Active |
Competing Products
20 competing products in Primary Myelofibrosis (PMF)